Cargando…
Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma
BACKGROUND: Neuroblastoma is a paediatric cancer that is characterised by poor prognosis for chemoresistant disease, highlighting the need for better treatment options. Here, we asked whether BH3-mimetics inhibiting BCL2 proteins may eliminate chemoresistant neuroblastoma cells. METHODS: We utilised...
Autores principales: | Jacob, Maureen, Wiedemann, Sara, Brücher, Daniela, Pieper, Nadja M., Birkhold, Moni, Särchen, Vinzenz, Jeroch, Jan, Demes, Melanie C., Gretser, Steffen, Braun, Yannick, Gradhand, Elise, Rothweiler, Florian, Michaelis, Martin, Cinatl, Jindrich, Vogler, Meike |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646009/ https://www.ncbi.nlm.nih.gov/pubmed/37723317 http://dx.doi.org/10.1038/s41416-023-02430-8 |
Ejemplares similares
-
Pediatric multicellular tumor spheroid models illustrate a therapeutic potential by combining BH3 mimetics with Natural Killer (NK) cell-based immunotherapy
por: Särchen, Vinzenz, et al.
Publicado: (2022) -
Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML
por: Ewald, Larissa, et al.
Publicado: (2019) -
A direct comparison of selective BH3-mimetics reveals BCL-X(L), BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma
por: Bierbrauer, Annika, et al.
Publicado: (2020) -
Selective BH3 mimetics synergize with BET inhibition to induce mitochondrial apoptosis in rhabdomyosarcoma cells
por: Erdogdu, Ufuk, et al.
Publicado: (2021) -
Computational modeling of DLBCL predicts response to BH3-mimetics
por: Cloete, Ielyaas, et al.
Publicado: (2023)